Reprogramming Immunity to Treat Resistant Cancers
At IngenOx, we’re building a global oncology company focused on helping patients with advanced cancers that are resistant to chemotherapy and current immunotherapies.
These cancers are difficult to treat because they can evade immune detection. They often produce very few warning signals (tumour antigens), making them nearly invisible to existing immune-based therapies. For patients with these cancers, the standard of care—chemo- or immunotherapy—offers limited benefit and may cause serious side effects.
We aim to change that.
Our precision medicines, including cancer vaccines, are designed to reveal hidden cancers and enable the immune system to recognise and destroy them. By using our novel drugs and vaccines, we’re developing safer, more effective treatments for patients who currently have few viable options.
At IngenOx, we advance our therapies for cancer patients with urgent clinical unmet needs.
Pipeline Designed for Real-World Impact
IngenOx is developing a portfolio of drugs and vaccines to help patients with advanced cancers who have limited treatment options.
Our innovative and complementary assets are advancing through clinical development with the goal of bringing safer, more effective therapies to the patients who need them most.
IngenOx Product Highlights
Zabadinostat (CXD101)
A drug with a differentiated safety profile and demonstrated clinical activity.
Clinically validated in lymphoma and microsatellite-stable (MSS) colorectal cancer, with an ongoing trial in liver cancer showing early signals of survival benefit.
PRMT5 Inhibitor (AT101)
A small molecule inhibitor of PRMT5, developed through our in-house drug discovery process. Currently undergoing IND-enabling studies and paired with a companion diagnostic to help identify patients most likely to benefit from treatment.
Cancer Vaccine (PCV001)
A precision cancer vaccine developed through our in-house platform, designed to prevent relapse or spread of colorectal cancer. Entering Phase 1 clinical studies.
About IngenOx
IngenOx Therapeutics is a clinical-stage biopharmaceutical company based in Oxford, UK, developing innovative drugs and vaccines to treat some of the most aggressive and treatment-resistant cancers.
Formed in 2023 through the merger of two Oxford University spinouts—Celleron Therapeutics and Argonaut Therapeutics—IngenOx combines deep expertise in drug discovery and clinical development. This integration strengthens our scientific capabilities and ensures continuity across our clinical pipeline.
Our experienced leadership team brings together internationally recognised cancer scientists and industry experts with a strong track record in translational medicine and commercial strategy.
We are advancing a pipeline of clinical assets designed to target immunologically cold tumours through precision drugs and cancer vaccines. Our in-house platform supports both small molecule drug discovery and vaccine development, enabling the generation of highly targeted therapies across multiple tumour types.
Mission & Vision
Our Mission is to develop safe and effective treatments for cancers with unmet clinical need through science and innovation.
Our Vision is to become a world-leading company in cancer drug development, with an advanced portfolio of clinical assets that make a meaningful difference for patients.
Partnering Opportunities
IngenOx is positioned for value growth by advancing its innovative drug candidates through clinical development toward regulatory approval and commercialisation.
Our competitive advantage lies in our ability to generate and develop assets through a fully integrated discovery-to-clinic model. With complete control over intellectual property and translational strategy, we are able to efficiently convert cutting-edge science into targeted therapies for patients facing the greatest need.
Strategic Collaboration
Our business model is centred on the discovery and development of novel cancer therapies, supported by strategic collaborations that enhance and accelerate our work.
Alongside our in-house drug and vaccine discovery capabilities, we maintain joint working relationships with established partners who contribute in-licensing, research and development expertise, and other growth-oriented opportunities.